Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

Cancer Immunotherapy Treatment Market on the Rise as R&D Increases

PR Newswire September 21, 2018

aTyr Pharma to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

GlobeNewswire September 20, 2018

aTyr Pharma to Present at the Baird 2018 Global Healthcare Conference

GlobeNewswire August 30, 2018

aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update

GlobeNewswire August 14, 2018

aTyr Pharma to Host Conference Call and Webcast of Second Quarter 2018 Financial Results on August 14, 2018

GlobeNewswire August 8, 2018

aTyr Pharma Appoints Jill Broadfoot as Chief Financial Officer

GlobeNewswire July 31, 2018

aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference

GlobeNewswire July 26, 2018

aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate

GlobeNewswire June 26, 2018

aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference

GlobeNewswire May 31, 2018

Benzinga Pro's 5 Stocks To Watch Today

Benzinga.com  May 17, 2018

aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference

GlobeNewswire May 17, 2018

Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings

Benzinga.com  May 16, 2018

Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

Benzinga.com  May 15, 2018

36 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  May 14, 2018

Mid-Day Market Update: Dow Rises 140 Points; Remark Holdings Shares Plunge

Benzinga.com  May 14, 2018

Mid-Morning Market Update: Markets Open Higher; Sears Board Explores Sale Of Assets

Benzinga.com  May 14, 2018

aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring

GlobeNewswire May 14, 2018

aTyr Pharma, Inc. to Host Earnings Call

Accesswire May 14, 2018

aTyr Pharma to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 14, 2018

GlobeNewswire May 8, 2018

aTyr Pharma Provides Mechanistic Update on Resokine Pathway at American Academy of Immunology Annual Meeting

GlobeNewswire May 2, 2018